Browse studies

Find your next paid study

60 recruiting studies matching your filters

A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of Acoramidis for Transthyretin Amyloidosis Prevention in the Young (ACT-EARLY Trial)

Transthyretin amyloidosis (ATTR) is a disease where the normally occurring transthyretin (TTR) protein falls apart and forms amyloid, a sticky plaque-like subs…

AmyloidosisAmyloid CardiomyopathyTransthyretin Amyloidosis+3 more

Estimated

~$10 – $8,750

Eidos Therapeutics, a BridgeBio companyNCT06563895

Phase 4

An Open-Label Study to Investigate the Long-Term Effects of Acoramidis on Cardiac Function, Structure and Cardiac Amyloid Burden in Participants With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

The study aims to evaluate the effect of acoramidis on cardiac functional and structural improvement in participants with ATTR-CM.

Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)AmyloidosisAmyloid Cardiomyopathy+1 more

Estimated

~$10 – $8,750

Eidos Therapeutics, a BridgeBio companyNCT07695701

Prospective Evaluation of Artificial Intelligence-enabled Screening for Transthyretin Amyloid Cardiomyopathy (ATTR-CM): TRACE-AI Prospective Study

The TRACE-AI Diagnostic Study will evaluate the performance of artificial intelligence (AI) models applied to electrocardiograms (AI-ECG) and echocardiograms (…

ATTR Amyloidosis With CardiomyopathyHeart Failure

Estimated

~$10 – $750

Yale UniversityNCT07398950

Phase 1

Phase 1 Study to Investigate the Dosimetry and Biodistribution of a Single Intravenous Administration of 99mTc-p5+14 Using SPECT/CT Imaging and Planar Gamma Scintigraphy in Healthy Volunteers and Patients With AL or ATTR Systemic Amyloidosis

This study will investigate 99mTc-p5+14, an amyloid-reactive synthetic peptide, p5+14, radiolabeled with technetium-99m, as a radiotracer for detecting paamylo…

Systemic Amyloidosis

Estimated

~$10 – $6,250

University of Tennessee Graduate School of MedicineNCT05951816

Artificial Intelligence Guided Echocardiographic Screening of Rare Diseases

Despite rapidly advancing developments in targeted therapeutics and genetic sequencing, persistent limits in the accuracy and throughput of clinical phenotypin…

Cardiac Amyloidosis

Estimated

~$10 – $750

Cedars-Sinai Medical CenterNCT05139797

Observational

Pilot Study Evaluating Supervised Cardiac Rehabilitation in Patients With Cardiac Amyloidosis

Exercise training in patients with heart failure and preserved ejection fraction (HFpEF) has been associated with an improvement in cardiorespiratory fitness a…

Cardiac Amyloidosis

Estimated

~$10 – $6,250

Wake Forest University Health SciencesNCT06096675

Phase 3

[64Cu]FBP8 PET for Early Detection of Intracardiac Thrombus in Amyloid Cardiomyopathy

The primary goal of this pilot study is to determine whether \[64Cu\]FBP8, a novel fibrin-binding positron emission tomography (PET) probe, can identify intrac…

Cardiac Amyloidosis

Estimated

~$10 – $6,250

Brigham and Women's HospitalNCT07560306

Multicenter Study for the Validation of an AI-based ECG Platform for Early Cardiac Amyloidosis Diagnosis (CONCERTO)

CONCERTO is a retrospective, observational, multicentric and single-arm study to perform an external validation of the cloud-based and AI-powered electrocardio…

Transthyretin Cardiac Amyloidosis

Estimated

~$10 – $1,125

Idoven 1903 S.L.NCT06978660

Phase 2

A Phase 2, Open-label, Randomized, Dose Optimization Study Evaluating the Efficacy and Safety of Belantamab Mafodotin Administered in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain Amyloidosis (ALANIS)

The study aims to evaluate the efficacy and safety of belantamab mafodotin in combination with cyclophosphamide, bortezomib, and dexamethasone in adult partici…

Amyloidosis

Estimated

~$10 – $7,500

GlaxoSmithKlineNCT07224672

Phase 2

A Phase 2 Clinical Trial of Teclistamab and Daratumumab in Previously Untreated AL Amyloidosis

The purpose of this study is to investigate whether teclistamab-daratumumab combination is effective and safe in AL amyloidosis. The study treatment is divide…

Amyloid Light-chain Amyloidosis

Estimated

~$10 – $7,500

Rajshekhar Chakraborty, MDNCT07110844

Phase 1

A Phase 1b/2 Study of AZD0120 (Also Known as GC012F), a Chimeric Antigen Receptor T Cell Therapy Targeting CD19 and B Cell Maturation Antigen in Participants With Relapsed or Refractory AL Amyloidosis.

Open-label Phase 1b/2 study with primary objective of this study is to evaluate the safety, tolerability and efficacy of AZD0120 in participants with light cha…

Relapsed AL AmyloidosisRefractory AL AmyloidosisLight Chain Amyloidosis+1 more

Estimated

~$10 – $8,750

Alexion Pharmaceuticals, Inc.NCT07081646

Phase 2

DapagliFLOzin in Renal AL Amyloidosis (FLORAL)

The goal of this clinical trial is to learn if an oral drug called dapagliflozin is safe and can reduce high protein levels in the urine of patients with renal…

Renal AL Amyloidosis

Estimated

~$10 – $7,500

Barbara Ann Karmanos Cancer InstituteNCT06420167